Globe News Wire
14 Nov 2025, 21:05 UTC · 44w ago
Verdict
Headline takes no side. We score ENTX +0.60 — strongly bullish.
+0.60strongly bullish
More positive than 70% of ticker scores this week
Which stocks this story touches
More positive than 70% of ticker scores this week
The company achieved an FDA agreement for its EB613 Phase 3 study and showed consistent efficacy data, though it continues to operate at a net loss.
More positive than 59% of ticker scores this week
The company is collaborating on promising pre-clinical data for oral OXM and GLP-2 programs.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 79% of relationship scores this week
[mutual] Entera Bio and OPKO Health are collaborating on oral GLP-2 and oral OXM programs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
3d ago
+9.2%
Price agrees with the score
$2.96 vs $2.71 close before publication (Nov 14) · not market-adjusted
ENTX chart →
